questionsmedicales.fr
États, signes et symptômes pathologiques
Processus pathologiques
Processus néoplasiques
Processus néoplasiques : Questions médicales fréquentes
Termes MeSH sélectionnés :
Complement Inactivating Agents
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Processus néoplasiques : Questions médicales les plus fréquentes",
"headline": "Processus néoplasiques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Processus néoplasiques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-18",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Processus néoplasiques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Processus pathologiques",
"url": "https://questionsmedicales.fr/mesh/D010335",
"about": {
"@type": "MedicalCondition",
"name": "Processus pathologiques",
"code": {
"@type": "MedicalCode",
"code": "D010335",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Anaplasie",
"alternateName": "Anaplasia",
"url": "https://questionsmedicales.fr/mesh/D000708",
"about": {
"@type": "MedicalCondition",
"name": "Anaplasie",
"code": {
"@type": "MedicalCode",
"code": "D000708",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.045"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Carcinogenèse",
"alternateName": "Carcinogenesis",
"url": "https://questionsmedicales.fr/mesh/D063646",
"about": {
"@type": "MedicalCondition",
"name": "Carcinogenèse",
"code": {
"@type": "MedicalCode",
"code": "D063646",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.098"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Transformation cellulaire néoplasique",
"alternateName": "Cell Transformation, Neoplastic",
"url": "https://questionsmedicales.fr/mesh/D002471",
"about": {
"@type": "MedicalCondition",
"name": "Transformation cellulaire néoplasique",
"code": {
"@type": "MedicalCode",
"code": "D002471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.098.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Crise blastique",
"alternateName": "Blast Crisis",
"url": "https://questionsmedicales.fr/mesh/D001752",
"about": {
"@type": "MedicalCondition",
"name": "Crise blastique",
"code": {
"@type": "MedicalCode",
"code": "D001752",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.098.500.110"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Crise blastique",
"alternateName": "Blast Crisis",
"url": "https://questionsmedicales.fr/mesh/D001752",
"about": {
"@type": "MedicalCondition",
"name": "Crise blastique",
"code": {
"@type": "MedicalCode",
"code": "D001752",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.098.500.110"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cocancérogenèse",
"alternateName": "Cocarcinogenesis",
"url": "https://questionsmedicales.fr/mesh/D003043",
"about": {
"@type": "MedicalCondition",
"name": "Cocancérogenèse",
"code": {
"@type": "MedicalCode",
"code": "D003043",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.098.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Invasion tumorale",
"alternateName": "Neoplasm Invasiveness",
"url": "https://questionsmedicales.fr/mesh/D009361",
"about": {
"@type": "MedicalCondition",
"name": "Invasion tumorale",
"code": {
"@type": "MedicalCode",
"code": "D009361",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.645"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Infiltration leucémique",
"alternateName": "Leukemic Infiltration",
"url": "https://questionsmedicales.fr/mesh/D017254",
"about": {
"@type": "MedicalCondition",
"name": "Infiltration leucémique",
"code": {
"@type": "MedicalCode",
"code": "D017254",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.645.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Métastase tumorale",
"alternateName": "Neoplasm Metastasis",
"url": "https://questionsmedicales.fr/mesh/D009362",
"about": {
"@type": "MedicalCondition",
"name": "Métastase tumorale",
"code": {
"@type": "MedicalCode",
"code": "D009362",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Extension extranodale",
"alternateName": "Extranodal Extension",
"url": "https://questionsmedicales.fr/mesh/D000079822",
"about": {
"@type": "MedicalCondition",
"name": "Extension extranodale",
"code": {
"@type": "MedicalCode",
"code": "D000079822",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650.280"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Métastase lymphatique",
"alternateName": "Lymphatic Metastasis",
"url": "https://questionsmedicales.fr/mesh/D008207",
"about": {
"@type": "MedicalCondition",
"name": "Métastase lymphatique",
"code": {
"@type": "MedicalCode",
"code": "D008207",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650.560"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Micrométastase tumorale",
"alternateName": "Neoplasm Micrometastasis",
"url": "https://questionsmedicales.fr/mesh/D061206",
"about": {
"@type": "MedicalCondition",
"name": "Micrométastase tumorale",
"code": {
"@type": "MedicalCode",
"code": "D061206",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650.695"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Essaimage tumoral",
"alternateName": "Neoplasm Seeding",
"url": "https://questionsmedicales.fr/mesh/D009366",
"about": {
"@type": "MedicalCondition",
"name": "Essaimage tumoral",
"code": {
"@type": "MedicalCode",
"code": "D009366",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650.830"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Métastases d'origine inconnue",
"alternateName": "Neoplasms, Unknown Primary",
"url": "https://questionsmedicales.fr/mesh/D009382",
"about": {
"@type": "MedicalCondition",
"name": "Métastases d'origine inconnue",
"code": {
"@type": "MedicalCode",
"code": "D009382",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650.895"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cellules tumorales circulantes",
"alternateName": "Neoplastic Cells, Circulating",
"url": "https://questionsmedicales.fr/mesh/D009360",
"about": {
"@type": "MedicalCondition",
"name": "Cellules tumorales circulantes",
"code": {
"@type": "MedicalCode",
"code": "D009360",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.650.900"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Récidive tumorale locale",
"alternateName": "Neoplasm Recurrence, Local",
"url": "https://questionsmedicales.fr/mesh/D009364",
"about": {
"@type": "MedicalCondition",
"name": "Récidive tumorale locale",
"code": {
"@type": "MedicalCode",
"code": "D009364",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.655"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Maladie résiduelle",
"alternateName": "Neoplasm, Residual",
"url": "https://questionsmedicales.fr/mesh/D018365",
"about": {
"@type": "MedicalCondition",
"name": "Maladie résiduelle",
"code": {
"@type": "MedicalCode",
"code": "D018365",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dépendance oncogène",
"alternateName": "Oncogene Addiction",
"url": "https://questionsmedicales.fr/mesh/D000074723",
"about": {
"@type": "MedicalCondition",
"name": "Dépendance oncogène",
"code": {
"@type": "MedicalCode",
"code": "D000074723",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.550.727.850"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Processus néoplasiques",
"alternateName": "Neoplastic Processes",
"code": {
"@type": "MedicalCode",
"code": "D009385",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Barbara A Centeno",
"url": "https://questionsmedicales.fr/author/Barbara%20A%20Centeno",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology, Moffitt Cancer Center, Tampa, Florida, USA, Barbara.Centeno@moffitt.org."
}
},
{
"@type": "Person",
"name": "Sarah C Thomas",
"url": "https://questionsmedicales.fr/author/Sarah%20C%20Thomas",
"affiliation": {
"@type": "Organization",
"name": "Office of Chief Medical Examiner, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Guoqiang Zeng",
"url": "https://questionsmedicales.fr/author/Guoqiang%20Zeng",
"affiliation": {
"@type": "Organization",
"name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China."
}
},
{
"@type": "Person",
"name": "Honglan Zhou",
"url": "https://questionsmedicales.fr/author/Honglan%20Zhou",
"affiliation": {
"@type": "Organization",
"name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China."
}
},
{
"@type": "Person",
"name": "Yuantao Wang",
"url": "https://questionsmedicales.fr/author/Yuantao%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Urological Department, First Hospital of Jilin University, Changchun 130021, Jilin Province, China. Electronic address: wangyuantaobs@jlu.edu.cn."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The complement inhibitor CD59 is required for GABAergic synaptic transmission in the dentate gyrus.",
"datePublished": "2023-04-05",
"url": "https://questionsmedicales.fr/article/37027303",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.celrep.2023.112349"
}
},
{
"@type": "ScholarlyArticle",
"name": "Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37239905",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24108561"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.",
"datePublished": "2022-12-08",
"url": "https://questionsmedicales.fr/article/36476151",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10600280221138802"
}
},
{
"@type": "ScholarlyArticle",
"name": "Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.",
"datePublished": "2022-09-20",
"url": "https://questionsmedicales.fr/article/36127336",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-022-33003-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.",
"datePublished": "2022-09-15",
"url": "https://questionsmedicales.fr/article/36110036",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/imr.13137"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Processus pathologiques",
"item": "https://questionsmedicales.fr/mesh/D010335"
},
{
"@type": "ListItem",
"position": 4,
"name": "Processus néoplasiques",
"item": "https://questionsmedicales.fr/mesh/D009385"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Processus néoplasiques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Processus néoplasiques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Processus néoplasiques",
"description": "Comment diagnostiquer un cancer ?\nQuels tests sont utilisés pour le dépistage ?\nQu'est-ce qu'une biopsie ?\nQuels sont les marqueurs tumoraux ?\nComment évaluer le stade d'un cancer ?",
"url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Inactivating+Agents&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Processus néoplasiques",
"description": "Quels sont les symptômes courants du cancer ?\nComment reconnaître une tumeur ?\nQuels signes indiquent un cancer avancé ?\nLes symptômes varient-ils selon le type de cancer ?\nQu'est-ce que la cachexie ?",
"url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Inactivating+Agents&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Processus néoplasiques",
"description": "Comment prévenir le cancer ?\nLe vaccin contre le HPV prévient-il le cancer ?\nQuels aliments aident à prévenir le cancer ?\nL'exercice physique réduit-il le risque de cancer ?\nLe dépistage précoce est-il important ?",
"url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Inactivating+Agents&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Processus néoplasiques",
"description": "Quels sont les traitements standards du cancer ?\nQu'est-ce que l'immunothérapie ?\nComment fonctionne la radiothérapie ?\nQuels sont les effets secondaires de la chimiothérapie ?\nQuand est-ce que la chirurgie est nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Inactivating+Agents&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Processus néoplasiques",
"description": "Quelles sont les complications du cancer ?\nComment les métastases affectent-elles le traitement ?\nQu'est-ce que la douleur cancéreuse ?\nLes traitements peuvent-ils causer des complications ?\nComment gérer les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Inactivating+Agents&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Processus néoplasiques",
"description": "Quels sont les principaux facteurs de risque du cancer ?\nL'hérédité joue-t-elle un rôle dans le cancer ?\nLe stress est-il un facteur de risque ?\nL'exposition à des produits chimiques augmente-t-elle le risque ?\nL'alimentation influence-t-elle le risque de cancer ?",
"url": "https://questionsmedicales.fr/mesh/D009385?mesh_terms=Complement+Inactivating+Agents&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des examens cliniques, imageries et biopsies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le dépistage ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent mammographies, coloscopies et tests sanguins spécifiques."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une biopsie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une biopsie consiste à prélever un échantillon de tissu pour analyse histologique."
}
},
{
"@type": "Question",
"name": "Quels sont les marqueurs tumoraux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs tumoraux sont des substances produites par les cellules cancéreuses, détectables dans le sang."
}
},
{
"@type": "Question",
"name": "Comment évaluer le stade d'un cancer ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stade est évalué par des examens d'imagerie et des classifications comme TNM."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants du cancer ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, perte de poids, douleurs et changements cutanés."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une tumeur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une tumeur peut se manifester par une masse palpable, des douleurs ou des changements fonctionnels."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent un cancer avancé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des douleurs persistantes, des saignements inexpliqués et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque type de cancer présente des symptômes spécifiques selon l'organe touché."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la cachexie ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La cachexie est une perte de poids et de masse musculaire souvent associée au cancer."
}
},
{
"@type": "Question",
"name": "Comment prévenir le cancer ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut un mode de vie sain, l'évitement du tabac et des dépistages réguliers."
}
},
{
"@type": "Question",
"name": "Le vaccin contre le HPV prévient-il le cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vaccin contre le HPV réduit le risque de cancers liés au virus, comme le cancer du col."
}
},
{
"@type": "Question",
"name": "Quels aliments aident à prévenir le cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les fruits, légumes, grains entiers et aliments riches en antioxydants sont bénéfiques."
}
},
{
"@type": "Question",
"name": "L'exercice physique réduit-il le risque de cancer ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier est associé à un risque réduit de plusieurs types de cancer."
}
},
{
"@type": "Question",
"name": "Le dépistage précoce est-il important ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage précoce permet de détecter le cancer à un stade plus traitable."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements standards du cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent chirurgie, chimiothérapie, radiothérapie et immunothérapie."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que l'immunothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunothérapie utilise le système immunitaire pour combattre les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Comment fonctionne la radiothérapie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie utilise des rayonnements pour détruire les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections."
}
},
{
"@type": "Question",
"name": "Quand est-ce que la chirurgie est nécessaire ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour retirer des tumeurs localisées ou pour un diagnostic."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du cancer ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent métastases, infections, et effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Comment les métastases affectent-elles le traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les métastases compliquent le traitement et peuvent nécessiter des approches plus agressives."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la douleur cancéreuse ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur cancéreuse est causée par la tumeur ou les traitements, nécessitant une gestion adéquate."
}
},
{
"@type": "Question",
"name": "Les traitements peuvent-ils causer des complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements comme la chimiothérapie peuvent entraîner des complications comme des infections."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des traitements ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut des médicaments, des soins de soutien et des conseils nutritionnels."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du cancer ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'alcool, l'obésité et l'exposition à des agents carcinogènes."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans le cancer ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer augmentent le risque de certains types de cancer."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut influencer le risque de cancer, bien que les preuves soient variées."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques augmente-t-elle le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques comme l'amiante ou le benzène est un facteur de risque."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de cancer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en graisses et pauvre en fibres peut augmenter le risque de cancer."
}
}
]
}
]
}
Complement-dependent microglia pruning of excitatory synapses has been widely reported in physiological and pathological conditions, with few reports concerning pruning of inhibitory synapses or direc...
CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericid...
To review the pharmacology, pharmacokinetics, efficacy, safety, dosing and administration, and place in therapy of sutimlimab for the management of cold agglutinin disease (CAD)-associated hemolysis....
A literature search of PubMed (1966-October 2022) was conducted using the keywords...
All published prospective clinical trials, prescribing information, and meeting abstracts on sutimlimab for the treatment of CAD were reviewed....
Sutimlimab is a first-in-class complement C1s inhibitor indicated for the treatment of CAD-associated hemolysis. This approval was based on the phase III CARDINAL trial, which evaluated sutimlimab in ...
Sutimlimab rapidly halts hemolysis, improves hemoglobin, and improves quality-of-life in patients with CAD. Safety issues with sutimlimab include infusion-related reactions and risk of serious infecti...
Sutimlimab provides an additional therapeutic option in the treatment of CAD-associated hemolysis that can lead to rapid improvement in hemoglobin and anemia-related symptoms....
With the addition of the compstatin-based complement C3 inhibitor pegcetacoplan, another class of complement targeted therapeutics have recently been approved. Moreover, compstatin derivatives with en...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal, not malignant, hematological disease characterized by intravascular hemolysis, thrombophilia and bone marrow failure. While this latter pres...
This article presents the results of group discussion among an ad hoc constituted panel of experts aimed at identifying and addressing unmet clinical needs (UCNs) in the management of infectious risk ...
BACKGROUND Secondary thrombotic microangiopathies (TMAs) are induced by several underlying conditions and most are resolved by treating the underlying disease. Eculizumab, a human monoclonal antibody,...
Over a century after the discovery of the complement system, the first complement therapeutic was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It was a long-acting monoclon...
Paul Ehrlich was a pioneering Immunobiologist and physician who coined the term 'complement' in the year 1899. He was a leading visionary scientist who worked in the late 19th and early 20th centuries...
Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a s...